SQ - Cerecor shares surge 23% on initial results from early-stage CERC-002 Crohn's disease trial

Cerecor  (CERC) shares surge over 23% after posting positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease ((CD)).The trial is designed to initially evaluate two doses of CERC-002 – 1 mg/kg SQ every two weeks and 3 mg/kg SQ every two weeks, with a treatment period of eight weeks. Study showed positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments.Clinically meaningful endoscopic improvement in 75% (3/4) of subjects were observed, as determined by colonoscopy, the company said.CERC-002 was well tolerated with no drug-related severe adverse events.The company also said that the second cohort of the study is fully enrolled, and it expects to post complete data in the second half of this year.

For further details see:

Cerecor shares surge 23% on initial results from early-stage CERC-002 Crohn's disease trial